Stephen R Fussell Net Worth

The estimated Net Worth of Stephen R Fussell is at least $47.2 Milione dollars as of 23 April 2019. Stephen Fussell owns over 56,000 units of Abbott Laboratories stock worth over $26,344,021 and over the last 19 years Stephen sold ABT stock worth over $20,905,122.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Fussell ABT stock SEC Form 4 insiders trading

Stephen has made over 62 trades of the Abbott Laboratories stock since 2005, according to the Form 4 filled with the SEC. Most recently Stephen exercised 56,000 units of ABT stock worth $2,632,000 on 23 April 2019.

The largest trade Stephen's ever made was exercising 388,983 units of Abbott Laboratories stock on 30 January 2018 worth over $14,516,846. On average, Stephen trades about 19,985 units every 59 days since 2005. As of 23 April 2019 Stephen still owns at least 225,935 units of Abbott Laboratories stock.

You can see the complete history of Stephen Fussell stock trades at the bottom of the page.

What's Stephen Fussell's mailing address?

Stephen's mailing address filed with the SEC is 100 ABBOTT PARK ROAD, , ABBOTT PARK, IL, 60064-6400.

Insiders trading at Abbott Laboratories

Over the last 24 years, insiders at Abbott Laboratories have traded over $388,257,551 worth of Abbott Laboratories stock and bought 1,028,477 units worth $44,923,618 . The most active insiders traders include Miles D White, Richard A Gonzalez e Jeffrey M Leiden. On average, Abbott Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,003,344. The most recent stock trade was executed by John A. Jr. Mccoy on 1 September 2024, trading 27 units of ABT stock currently worth $3,100.

What does Abbott Laboratories do?

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.

Complete history of Stephen Fussell stock trades at Abbott Laboratories

Abbott Laboratories executives and stock owners

Abbott Laboratories executives and other stock owners filed with the SEC include:

• Miles White,
  Executive Chairman of the Board
• Robert Ford,
  President, Chief Executive Officer, Director
• Lisa Earnhardt,
  Executive Vice President - Medical Devices
• Hubert Allen,
  Executive Vice President, General Counsel, Secretary
• Miles D. White M.B.A.,
  Exec. Chairman
• Daniel Salvadori,
  Executive Vice President - Nutritional Products
• Robert B. Ford,
  Chairman, Pres & CEO
• John Capek,
  Executive Vice President - Ventures
• Robert E. Funck Jr.,
  Exec. VP of Fin. & CFO
• Hubert L. Allen,
  Exec. VP, Gen. Counsel & Sec.
• Daniel Gesua Sive Salvadori,
  Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products
• John F. Ginascol,
  Exec. VP of Core Diagnostics
• Robert Alpern,
  Independent Director
• Sally Blount,
  Independent Director
• Glenn Tilton,
  Independent Director
• Samuel Scott,
  Independent Director
• William Osborn,
  Lead Independent Director
• Roxanne Austin,
  Independent Director
• Edward Liddy,
  Independent Director
• Phebe Novakovic,
  Independent Director
• Nancy McKinstry,
  Independent Director
• Michelle Kumbier,
  Independent Director
• John Stratton,
  Independent Director
• Daniel Starks,
  Independent Director
• Darren McDew,
  Independent Director
• Randel Woodgrift,
  Senior Vice President - CRM
• Alejandro Wellisch,
  Senior Vice President - Established Pharmaceuticals, Latin America
• Jared Watkin,
  Senior Vice President - Diabetes Care
• Christopher Scoggins,
  Senior Vice President - Rapid Diagnostics
• Michael Pederson,
  Senior Vice President - Electrophysiology and Heart Failure
• Joseph Manning,
  Senior Vice President - Nutrition International
• Sammy Karam,
  Senior Vice President - Established Pharmaceuticals, Emerging Markets
• Michael Dale,
  Senior Vice President - Structural Heart
• Jaime Contreras,
  Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
• Charles Brynelsen,
  Senior Vice President - Abbott Vascular
• Roger Bird,
  Senior Vice President - U.S. Nutrition
• Andrea Wainer,
  Executive Vice President - Rapid and Molecular Diagnostics
• Andrew Lane,
  Executive Vice President - Established Pharmaceuticals
• John Ginascol,
  Executive Vice President - Core Diagnostics
• Mary Moreland,
  Executive Vice President of Human Resources
• Robert Funck,
  Chief Financial Officer, Executive Vice President - Finance
• Gregory A. Ahlberg,
  Sr. VP of Core Laboratory Diagnostics & Commercial Operations
• Elaine R. Leavenworth,
  Sr. VP and Chief Marketing & External Affairs Officer
• Melissa Brotz,
  VP of Public Affairs & Corp. Marketing
• James E. Young,
  VP and Chief Ethics & Compliance Officer
• Scott Michael Leinenweber,
  VP of Investor Relations, Licensing & Acquisitions
• Sean Shrimpton,
  Senior Vice President
• Deepak S. Nath,
  Senior Vice President
• Brian B Yoor,
  Executive Vice President & CFO
• Brian J Blaser,
  Senior Vice President
• Stephen R Fussell,
  Senior Vice President
• Michael J Warmuth,
  Senior Vice President
• Eric S Fain,
  Senior Vice President
• Sharon J Bracken,
  Senior Vice President
• Michael T Rousseau,
  Pres., Cardiovasc. & Neuromod.
• Richard W Ashley,
  Executive Vice President
• Christopher J. Calamari,
  SENIOR VICE PRESIDENT
• Julie L. Tyler,
  SENIOR VICE PRESIDENT
• Jean Yves Pavee,
  Senior Vice President
• W James Farrell,
  Director
• Thomas C Freyman,
  Senior Vice President
• Georges H. De Vos,
  Senior Vice President
• Katherine C. Doyle,
  Senior Vice President
• J. Scott White,
  Senior Vice President
• Charles D Foltz,
  Senior Vice President
• Murthy V Simhambhatla,
  Senior Vice President
• Thomas G Frinzi,
  Senior Vice President
• John C Landgraf,
  Senior Vice President
• Greg W Linder,
  Vice President
• Heather L Mason,
  Senior Vice President
• Paul K Magill,
  Senior Vice President
• A. David Forrest,
  Senior Vice President
• H Laurance Fuller,
  Director
• Carlos Alban,
  Senior Vice President
• James V Mazzo,
  Senior Vice President
• Holger A Liepmann,
  Senior Vice President
• William D Smithburg,
  Director
• Laura J Schumacher,
  Senior Vice President
• David Owen,
  Director
• Edward L. Michael,
  Senior Vice President
• Richard A Gonzalez,
  Chief Operating Officer
• Donald V Jr Patton,
  Senior Vice President
• William M Daley,
  Director
• Robert B Hance,
  Senior Vice President
• Mary T Szela,
  Senior Vice President
• Roy S Roberts,
  Director
• Corlis D Murray,
  Senior Vice President
• Thomas F Chen,
  Senior Vice President
• Olivier Bohuon,
  Senior Vice President
• James L Tyree,
  Senior Vice President
• W Ann Reynolds,
  Director
• Boone Jr Powell,
  Director
• Edward J Fiorentino,
  Senior Vice President
• Gary E Mccullough,
  Senior Vice President
• Jeffrey M Leiden,
  President & COO
• Jack M Greenberg,
  Director
• Joseph M Nemmers,
  Senior Vice President
• John R Walter,
  Director
• Jeffrey R Binder,
  Senior Vice President
• William G Dempsey,
  Senior Vice President
• A Barry Rand,
  Director
• Thomas M Wascoe,
  Senior Vice President
• Christopher B Begley,
  Senior Vice President
• Lance B Wyatt,
  Senior Vice President
• Guillermo A Herrera,
  Senior Vice President
• Lasa Jose M De,
  Senior Vice President
• Fernando Mateus,
  SENIOR VICE PRESIDENT
• Gregory A Ahlberg,
  SENIOR VICE PRESIDENT
• John A. Jr. Mccoy,
  VICE PRESIDENT
• Philip P Boudreau,
  EXECUTIVE VICE PRESIDENT
• Claire Babineaux Fontenot,
  
• Michael O'grady,
  
• Louis H. Morrone,
  EXECUTIVE VICE PRESIDENT
• Patricia Paola Gonzalez,
  
• Michael F Roman,